Gastrointestinal stromal tumor (GIST) is the most common benign mesenchymal tumor of the gastrointestinal tract. It has a high incidence in China. Because of the lack of specificity in the early stage of the disease, it is highly susceptible to malignant transformation and is prone to drug resistance. The high recurrence rate and insensitivity to chemoradiation are increasingly affecting the quality of life of patients. Immunotherapy is an emerging method for precise, rapid, safe and efficient diagnosis and treatment. It is currently used to treat a variety of tumors such as melanoma, non-small cell lung cancer, kidney cancer and prostate cancer, and has achieved satisfactory results. This article aims to summarize the main points of immunotherapy related to gastrointestinal stromal tumors at home and abroad, in order to further study its mechanism of action and lay a theoretical foundation for larger clinical trials.